• M2M money train

    SA's biggest mobile operators have found a new revenue stream, says Gugu Lourie.

  • Customers as experts

    Some M4Jam micro jobbers are now helping others to refine their ability to make money.

  • Sticking it to Sanral

    The time is now for citizen-centric leadership to stop the road to ruin, says Mandi Smallhorne.

Data provided by iNet BFA
Loading...
See More

Aspen boosts profit, Asian unit robust

Sep 12 2012 15:11 Reuters

Company Data

ASPEN PHARMACARE HOLDINGS LIMITED [JSE:APN]

Last traded 303.70
Change -2.2
% Change -0.01
Cumulative volume 702998
Market cap 138.59bn

Last Updated: 20/08/2014 at 04:27. Prices are delayed by 15 minutes. Source: McGregor BFA

ADCOCK INGRAM HOLDINGS LIMITED [JSE:AIP]

Last traded 47.88
Change 0.09
% Change 0.00
Cumulative volume 140045
Market cap 8.41bn

Last Updated: 20/08/2014 at 04:23. Prices are delayed by 15 minutes. Source: McGregor BFA

Related Articles

Aspen: Earning to between rise 18%-24%

Aspen unit to buy drug portfolio from GSK

Drug firms win R2.5bn tender

Aspen prepared to help bridge ARV shortages

Aspen buys GSK brands

Aspen buys GSK Aussie drugs for R2.2bn

 

Johannesburg - Drugs maker Aspen Pharmacare [JSE:APN] booked a 22% rise in full-year profit, helped by a robust showing in its Asia-Pacific unit.

Aspen, 19% owned by Britain GlaxoSmithKline, said in financial results released on Wednesday its normalised diluted headline earnings per share totalled 636.2 cents in the year to end-June compared with 523.3 cents a year earlier.

The biggest generic drugs maker in the southern hemisphere, Aspen is one of the companies most likely to benefit as some of best-selling name-brand drugs worth more than $100bn lose patent protection over the next three years.

Sales increased 23% to R15.3bn with its Asia-Pacific unit doubling its revenue to R6bn thanks to an acquisition.

Durban-based Aspen completed the acquisition of the generic business of Australia's Sigma Pharmaceuticals last year, boosting its presence in the region.

The company said it is looking to expand further in fast-growing Latin America, where it has small operations in Brazil, Venezuela and Mexico.

Shares in Aspen, which are up about 44% so far this year, were down 1.16% at R139.36, in line with its closest domestic rival Adcock Ingram Holdings [JSE:AIP], which was down 1.35% at R59.


*Follow Fin24 on Twitter, Facebook, Google+ and Pinterest.

 
aspen pharmacare holdings
NEXT ON FIN24X

 
 
 

Read Fin24’s Comments Policy

24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
0 comments
Add your comment
Comment 0 characters remaining
 

Company Snapshot

We're talking about:

Money Clinic

Money Clinic
Do you have a question about your finances? We'll get an expert opinion.
Click here...
Loading...